A blood test can help predict how men with advanced prostate cancer will respond to specific treatments, say an international group of researchers at the Lawson Health Research Institute in Ontario, Memorial Sloan Kettering Cancer Center in New York City, and the Royal Marsden and Epic Sciences in London. The researchers say that doctors can use this information to develop targeted cancer treatments that improve survival rates.
The study involved 142 men with advanced prostate cancer who had undergone at least one round of hormone-targeting therapy without success. The researchers used a liquid biopsy test to analyze circulating tumor cells (cancer cells that enter the bloodstream and cause metastasis) in blood samples and determine whether the tumor cells contained a protein called AR-V7.
They found that men who tested positive for this protein responded better to taxane-based chemotherapy, and those who tested negative responded better to androgen-receptor signaling inhibitors. The blood test is available in the United States as the Oncotype DX AR-V7 Nucleus Detect.
Sourced from: JAMA Oncology